Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. Open. Download Table | Schema for CALGB trial CALGB trial schema from publication: Small Cell Lung Cancer: Have We Made Any Progress Over the . This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage .

Author: Tegami Moogunos
Country: Senegal
Language: English (Spanish)
Genre: Literature
Published (Last): 28 September 2004
Pages: 361
PDF File Size: 11.60 Mb
ePub File Size: 12.86 Mb
ISBN: 682-4-54614-142-6
Downloads: 13075
Price: Free* [*Free Regsitration Required]
Uploader: Tagrel

It was challenging to accrue patients with this disease. Taofeek Kunle Owonikoko, MD. It evaluated the optimization of chemoradiotherapy in limited-stage SCLC. Formal discussant Taofeek Kunle Owonikoko, 330610of Winship Cancer Institute of Emory University, Atlanta, said it has been controversial whether to use once-daily or twice-daily radiation therapy in this patient population.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

Survival in both arms was higher than previously reported. Updated Trial Findings View More. Expert Point of View: Radiation-related toxicities were lower than expected likely due to the use of modern RT techniques These inconclusive results suggest that either schedule can be used in caalgb setting.


Seidman, MD, and Charles E. There was one death in the twice-daily group and two in the once-daily group due to radiation pneumonitis.

The study enrolled patients with histologically or cytologically proven SCLC recruited from 73 centers in 7 European countries and Canada between and By Alice Goodman June 25, Advertisement. All analyses were done on an czlgb basis.

Adverse events were not significantly 330610 between the two groups as well, with the exception of more neutropenia in patients treated with twice-daily radiation therapy. There was no statistically significant overall survival difference between the groups.

High-dose radiation therapy to the lungs and esophagus in the once-daily arm did not seem to translate to a significant difference between the arms in terms of esophagitis or pneumonitis. Clinical Applications of Genomic Studies R.

Eighty percent of patients had stage III disease. An international randomised trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer and good performance status.


No statistically significant differences between the two groups were reported for the rates of progression-free survival or local or metastatic disease progression. Falgb overall survival was 30 months vs 25 months, a difference that is not statistically significant.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

In cqlgb trial, survival was higher than previously reported in other trials of this patient population, and radiation toxicities were lower than expected. Patients with any response were offered prophylactic cranial radiation therapy. A total of 25 patients in the twice-daily radiation therapy group and 32 in the once-daily radiation therapy group did not get concurrent chemoradiation therapy.